The creation of retatrutide, a novel dual agonist targeting both GLP-1 and GIP receptors, involves a complex complicated synthetic process. Early routes focused on amino acid chain fragment coupling, utilizing solid-phase synthesis methodologies to build the long peptide sequence. Subsequent study has explored alternative approaches, including enzy